ZA201108347B - Hydrochloride salt of ((1s,2s,4r)-4{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino}-7h-pyrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate - Google Patents

Hydrochloride salt of ((1s,2s,4r)-4{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino}-7h-pyrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate

Info

Publication number
ZA201108347B
ZA201108347B ZA2011/08347A ZA201108347A ZA201108347B ZA 201108347 B ZA201108347 B ZA 201108347B ZA 2011/08347 A ZA2011/08347 A ZA 2011/08347A ZA 201108347 A ZA201108347 A ZA 201108347A ZA 201108347 B ZA201108347 B ZA 201108347B
Authority
ZA
South Africa
Prior art keywords
pyrolo
hydroxycyclopentyl
inden
ylamino
pyrimidin
Prior art date
Application number
ZA2011/08347A
Other languages
English (en)
Inventor
Ian G Armitage
Reenu Chopra
Martin Ian Cooper
Marianne Langston
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of ZA201108347B publication Critical patent/ZA201108347B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA2011/08347A 2009-05-14 2011-11-14 Hydrochloride salt of ((1s,2s,4r)-4{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino}-7h-pyrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate ZA201108347B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21622109P 2009-05-14 2009-05-14
PCT/US2010/001415 WO2010132110A1 (en) 2009-05-14 2010-05-13 Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate

Publications (1)

Publication Number Publication Date
ZA201108347B true ZA201108347B (en) 2014-05-26

Family

ID=42396430

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/08347A ZA201108347B (en) 2009-05-14 2011-11-14 Hydrochloride salt of ((1s,2s,4r)-4{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino}-7h-pyrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate

Country Status (18)

Country Link
US (2) US9187482B2 (https=)
EP (2) EP3091020B1 (https=)
JP (3) JP2012526808A (https=)
KR (2) KR20170102381A (https=)
CN (2) CN102421780A (https=)
AU (1) AU2010248151B2 (https=)
BR (1) BRPI1012142A2 (https=)
CA (1) CA2761256C (https=)
IL (1) IL216201A (https=)
MX (1) MX2011012108A (https=)
NZ (2) NZ621128A (https=)
PE (2) PE20161222A1 (https=)
PH (1) PH12015501925A1 (https=)
RU (1) RU2562245C2 (https=)
SG (2) SG175929A1 (https=)
UA (1) UA108986C2 (https=)
WO (1) WO2010132110A1 (https=)
ZA (1) ZA201108347B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
WO2009042013A1 (en) * 2007-08-02 2009-04-02 Millennium Pharmaceuticals, Inc. Process for the synthesis of e1 activating enzyme inhibitors
SG175929A1 (en) 2009-05-14 2011-12-29 Millennium Pharm Inc Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
JP2013541587A (ja) * 2010-11-05 2013-11-14 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｎｅｄｄ８活性化酵素阻害剤の投与
SG11201400102WA (en) * 2011-08-24 2014-03-28 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
KR101987861B1 (ko) 2011-11-03 2019-06-11 밀레니엄 파머슈티컬스 인코퍼레이티드 Nedd-8 활성화 효소 억제제 및 저메틸화제의 투여
CN104136399B (zh) * 2012-02-17 2018-08-07 米伦纽姆医药公司 泛素活化酶的吡唑并嘧啶基抑制剂
JP2015524442A (ja) 2012-08-03 2015-08-24 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｕｂａ６のインドール置換ピロロピリミジニル阻害剤
EP2904115B1 (en) * 2012-10-01 2018-08-08 Millennium Pharmaceuticals, Inc. Biomarkers and methods to predict response to inhibitors and uses thereof
CA2923752A1 (en) 2013-05-14 2014-11-20 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents
CN105492429A (zh) 2013-07-02 2016-04-13 米伦纽姆医药公司 Sumo活化酶的杂芳基抑制剂
BR112016030787B1 (pt) 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso
CN106008394B (zh) * 2016-05-23 2018-12-04 中国人民解放军第二军医大学 巯基苯并噻唑酰胺类化合物及其制备与作为药物的用途
WO2019060536A1 (en) * 2017-09-21 2019-03-28 Millennium Pharmaceuticals, Inc. CO-CRYSTALLINE FORMS OF ((1S, 2S, 4R) -4- {4 - [(1S) -2,3-DIHYDRO-1H-INDEN-1-YLAMINO] -7H-PYRROLO [2,3-D] PYRIMIDIN -7-YL} -2-HYDROXYCYCLOPENTYL) METHYLSULFAMATE, THEIR FORMULATIONS AND USES
US20220133884A1 (en) * 2019-02-26 2022-05-05 Millennium Pharmaceuticals, Inc. Compounds useful as adjuvants
KR20210115680A (ko) 2020-03-16 2021-09-27 서희강 연설용 프롬프터
WO2022112951A1 (en) * 2020-11-25 2022-06-02 Takeda Pharmaceutical Company Limited Solid state forms of hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3622561A (en) 1969-08-18 1971-11-23 Univ Utah Nucleoside sugar esters of sulfamic acid and method for preparation of the same
US4252951A (en) * 1979-10-09 1981-02-24 Eli Lilly And Company Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid
JPS62108897A (ja) 1985-11-05 1987-05-20 Rikagaku Kenkyusho アスカマイシン誘導体及びその合成法並びに制癌剤
GB8813148D0 (en) 1988-06-03 1988-07-06 Glaxo Group Ltd Chemical compounds
GB8826205D0 (en) 1988-11-09 1988-12-14 Wellcome Found Heterocyclic compounds
US5726302A (en) 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5721356A (en) 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
US5864033A (en) 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
US5470898A (en) 1993-06-30 1995-11-28 Montell North America Inc. Sorbitol derivatives as nucleators and clarifiers for polyolefins, and polyolefin compositions obtained therewith
GB9325810D0 (en) 1993-12-17 1994-02-23 Zeneca Ltd Herbicidal composition
GB9325809D0 (en) 1993-12-17 1994-02-23 Zeneca Ltd Herbicidal composition
US6210917B1 (en) 1993-12-29 2001-04-03 The Regents Of The University Of California Method for suppressing multiple drug resistance in cancer cells
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US5973161A (en) 1996-03-18 1999-10-26 The University Of North Carolina At Chapel Hill Enantioselective synthesis of cyclopentenes
US5824657A (en) 1997-03-18 1998-10-20 Cubist Pharmaceuticals, Inc. Aminoacyl sulfamides for the treatment of hyperproliferative disorders
US6734283B1 (en) 1997-12-19 2004-05-11 Millennium Pharmaceuticals, Inc. Human proteins responsible for NEDD8 activation and conjugation
JPH11228422A (ja) 1998-02-16 1999-08-24 Mitsubishi Chemical Corp 抗マラリア剤
JPH11228446A (ja) 1998-02-16 1999-08-24 Mitsubishi Chemical Corp 抗マラリア剤
WO2002032920A2 (en) 2000-10-18 2002-04-25 Pharmasset Limited Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
ATE466581T1 (de) 2001-12-07 2010-05-15 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
AU2003248708A1 (en) 2002-06-17 2003-12-31 Isis Pharmaceuticals, Inc. Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
EP1651595A2 (en) 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US7338957B2 (en) 2003-08-28 2008-03-04 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1680431A1 (en) 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
CN101693695A (zh) 2004-03-30 2010-04-14 大正制药株式会社 嘧啶衍生物以及与其应用有关的治疗方法
US20050282818A1 (en) 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
PT1848718E (pt) 2005-02-04 2012-10-11 Millennium Pharm Inc Inibidores de enzimas de activação e1
KR101450535B1 (ko) * 2006-02-02 2014-10-14 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｅ１ 활성화 효소의 억제제
EA201501088A1 (ru) * 2006-08-08 2017-01-30 Миллениум Фармасьютикалз, Инк. Гетероарильные соединения, применяемые в качестве ингибиторов e1 активирующих ферментов
WO2009042013A1 (en) * 2007-08-02 2009-04-02 Millennium Pharmaceuticals, Inc. Process for the synthesis of e1 activating enzyme inhibitors
SG175929A1 (en) 2009-05-14 2011-12-29 Millennium Pharm Inc Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
KR101987861B1 (ko) 2011-11-03 2019-06-11 밀레니엄 파머슈티컬스 인코퍼레이티드 Nedd-8 활성화 효소 억제제 및 저메틸화제의 투여
CA2923752A1 (en) 2013-05-14 2014-11-20 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents

Also Published As

Publication number Publication date
US9187482B2 (en) 2015-11-17
JP2012526808A (ja) 2012-11-01
CA2761256C (en) 2021-01-05
JP2015096547A (ja) 2015-05-21
US20170000792A9 (en) 2017-01-05
KR20170102381A (ko) 2017-09-08
BRPI1012142A2 (pt) 2016-03-29
JP2017105816A (ja) 2017-06-15
UA108986C2 (uk) 2015-07-10
CN104016987A (zh) 2014-09-03
MX2011012108A (es) 2011-12-08
US20110021544A1 (en) 2011-01-27
CA2761256A1 (en) 2010-11-18
PE20161222A1 (es) 2016-12-01
NZ596470A (en) 2014-04-30
US10016427B2 (en) 2018-07-10
EP2430026A1 (en) 2012-03-21
NZ621128A (en) 2015-08-28
IL216201A (en) 2015-11-30
CN102421780A (zh) 2012-04-18
AU2010248151A1 (en) 2011-12-01
PH12015501925A1 (en) 2018-01-22
US20160030432A1 (en) 2016-02-04
WO2010132110A1 (en) 2010-11-18
EP3091020B1 (en) 2020-12-30
KR20120024715A (ko) 2012-03-14
SG175929A1 (en) 2011-12-29
RU2562245C2 (ru) 2015-09-10
EP3091020A2 (en) 2016-11-09
RU2011150826A (ru) 2013-06-20
PE20120907A1 (es) 2012-08-18
IL216201A0 (en) 2012-01-31
AU2010248151B2 (en) 2016-07-14
EP3091020A3 (en) 2017-01-11
SG10201402148SA (en) 2014-07-30

Similar Documents

Publication Publication Date Title
ZA201108347B (en) Hydrochloride salt of ((1s,2s,4r)-4{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino}-7h-pyrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
FIC20253002I1 (fi) Otsanimodi, tai sen farmaseuttisesti hyväksyttävä suola, mukaan lukien hydrokloridisuola
FIC20200051I1 (fi) Entrektinibi tai sen tautomeerit tai farmaseuttisesti hyväksyttävät suolat
FIC20240046I1 (fi) Vibegroni tai sen farmaseuttisesti hyväksyttävä suola
CY2024030I1 (el) Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις πρωτεϊνικης κινασης β
FIC20220043I1 (fi) Difelikefaliini, valinnaisesti farmaseuttisesti hyväksyttävänä suolana, hydraattina, solvaattina, happosuolahydraattina tai N-oksidina
FIC20190029I1 (fi) Brigatinibi tai sen farmaseuttisesti hyväksyttävä suola
LT3415515T (lt) Metil-{4,6-diamino-2-[1-(2-fluorbenzil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilkarbamato gamybos būdas
IL210447A0 (en) Icotinib hydrochloride, synthesis, crystalline forms, drug combinations, and uses thereof
IL208355A0 (en) Heterocyclic copmpounds as adenosine receptor antagonist
PL3345607T3 (pl) Sposoby modyfikowania wzrostu kości poprzez podanie antagonisty lub agonisty sost lub wise
BRPI0906744A2 (pt) Inserções de amortecimento de espuma
ZA200903889B (en) Process for the synthesis of moxifloxacin hydrochloride
SI2175857T1 (sl) Kristalna oblika (E) 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino) 2-pirimidinil)amino)benzonitrila
AP3521A (en) Crystalline forms of hydrochloride salt of (4a-r,9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1h-indeno [2,1-b]pyridine-6-carbonitrile and their use as hsd 1 inhibitors
EP2445891A4 (en) 5-CHAIN HETEROARYL DERIVATIVES AS SPHINOSINE-1-PHOSPHATE RECEPTOR AGONISTS
EP2364312A4 (en) SYNTHESIS OF CRYSTALLINE PALONOSETRON CHLORHYDRATE
IL196094A0 (en) Cyclopropyl amine derivatives as histamin h3 receptor modulators
IL206479A0 (en) Crystalline forms of palonosetron hydrochloride
EP1976844A4 (en) IMPROVED METHOD FOR PURE DULOXETIN HYDROCHLORIDE
IT1390756B1 (it) Processo per la sintesi di carbapenem mediante l'uso di nickel raney
GB0700830D0 (en) Crystalline duloxetine hydrochloride
ZA200806508B (en) Salt of CD80 Antagonist
DK2445909T3 (da) Derivater af 6,7-dihydro-5h-imidazo [1,2-a] imidazol-3-carboxylsyre amider
GB0612508D0 (en) Crystalline duloxetine hydrochloride